Parceria

Yong has more than 20 years of experience in the pharmaceutical industry. Prior to BeiGene, he has been engaged in business development work for AstraZeneca for over 11 years, participating in all key projects during the period, transaction types including product licensing, CSO collaboration, and asset divestment, M&A, and joint venture establishment. He has successfully facilitated various forms of business cooperation and introduced a variety of products through flexible transaction structures. The products include innovative large and small molecular drugs, mature products, traditional Chinese medicine, diagnostic tests, and medical devices covering multiple therapeutical areas.

Prior to this, he also served at UCB and Shanghai Ethypharm in strategy planning, business development, and project management. Yong holds a master’s degree in molecular biology from the Beijing bio-engineering institute and obtained his bachelor of Microbiology from Shandong University.

Mike Ellis, Ph.D., joined BeiGene in 2020 as Vice President, Alliance Management. He was previously Vice President of Business Operations at Pionyr Immunotherapeutics, where he led partnering, strategic portfolio planning, and corporate strategy initiatives. Prior to that, Mike spent five years as Senior Director of Alliance Management at Regeneron Pharmaceuticals. Over the course of his career, Mike has built a track record of driving corporate growth in highly innovative, entrepreneurial companies. Mike received a B.S. in biology from University of Iowa, a Ph.D. in molecular biology from University of California, Berkeley, and an MBA from the Wharton School at the University of Pennsylvania.

Clare Fisher ingressou na BeiGene em 2021 como Vice-Presidente Sênior de Desenvolvimento de Negócios e Fusões e Aquisições, trazendo mais de duas décadas de experiência em saúde em funções de liderança, incluindo desenvolvimento corporativo, negócios e estratégia.

Ela ingressou na BeiGene vinda da Kaleido, onde atuou como Diretora de Desenvolvimento Corporativo. Anteriormente, ela trabalhou na Shire plc (agora Takeda), onde foi Vice-Presidente do Grupo, Chefe Global de Transações e Desenvolvimento de Negócios, e Chefe Interina de Desenvolvimento Corporativo. Anteriormente, ocupou cargos de liderança em desenvolvimento de negócios na Cubist Pharmaceuticals, Blueprint Medicines e Genzyme Corporation.

A Sra. Fisher possui um B.S. em bioquímica pela Universidade de Bath, bem como um MBA pela Henley Management College no Reino Unido.

Toby Freyman, Ph.D., joined BeiGene in 2021 as Vice President, Business Development bringing 20 years of experience in healthcare strategy, R&D, and business development.  Dr. Freyman was most recently Head of Rare Disease and GI Business Development at Takeda’s Center for External Innovation where he led a team focused on building Takeda’s pipeline and Takeda’s Global Gene Therapy platform.  Prior to Takeda, he was in Corporate Development at Shire plc (acquired by Takeda) leading transactions, including in-licensing, strategic collaborations, out-licensing, investments, and spin-outs. Dr. Freyman holds a B.S. from Syracuse University and a Ph.D. in Materials Engineering from the Massachusetts Institute of Technology, where he received an NIH Graduate Fellowship through a joint program with Harvard and MIT.

Lucy Li, Ph.D., is Executive Director of Corporate Strategy, overseeing the development of the company’s strategy and growth plans. Dr. Li joined BeiGene in 2015 and has served in various leadership roles in Corporate Strategy and Investor Relations, including leadership of the development of BeiGene’s 10-year corporate strategy. Prior to joining BeiGene, Dr. Li was a strategic consultant with Navigant Consulting (now a Guidehouse company) and Campbell Alliance Consulting (now Syneos Health Consulting). During her consulting career, Dr. Li gained a diverse set of experiences across therapeutic and functional areas, including corporate and portfolio strategy, marketing, market access, and finance. Dr. Li received a bachelor’s degree from Peking University and a Ph.D. in neuroscience and neurology from Washington University in St. Louis.

Yan Blake Liu, M.D., MBA, joined BeiGene in March 2021 as Executive Director of the newly formed Clinical Business Development Insights (CBDi) group. Dr. Liu, a trained cardiologist from Beijing, brings nearly 20 years of experience in the U.S. biotech/pharmaceutical industry to BeiGene. His roles prior to joining BeiGene include Competitive Intelligence (CI) Lead for Hematology (including CAR-T) and Immuno-Oncology at Novartis; CI Lead for Opdivo in Melanoma, RCC and Lung at BMS; and Marketing Director, Cardiometabolic, at Quest Diagnostics. Dr. Liu leads the CBDi function to support Clinical Development in building BeiGene’s pipeline, enhancing business development opportunity search capabilities from external innovations, and assisting in the development of corporate strategy. Dr. Liu holds an M.D. from China Medical School and an MBA from the University of Maryland, College Park.

Lusong Luo, Ph.D., is Senior Vice President & Head of External Innovation, and one of BeiGene’s founding scientists. Prior to joining BeiGene in 2010, Dr. Luo was Senior Director of Discovery Biology at BioDuro. In addition to his current role at BeiGene, Dr. Luo serves as the acting CEO and President of MapKure, LLC, a clinical-stage precision medicines company jointly owned by BeiGene, SpringWorks Therapeutics and other investors, as well as a board member of MapKure and Boston Immune Technologies & Therapeutics, a BeiGene-partnered company. Dr. Luo previously held positions at BioDuro, a contract research, development and manufacturing organization (“CRDMO”), as Senior Director and Director of Discovery Biology; and GlaxoSmithKline Oncology CEDD, where he served as Group Manager, Research Investigator, and Principal Scientist. Dr. Luo was a key member of a number of teams that have contributed to the discovery and development of more than a dozen oncology clinical compounds, five of which have obtained regulatory approvals. Dr. Luo has published more than 60 research papers, reviews, and book chapters. He trained with Professor Christopher T. Walsh at Harvard Medical School and obtained his Ph.D. in biochemistry from the University of New Mexico.

Sean Qiu, CFA, joined BeiGene in December 2021 as Executive Director, Product Strategy & Valuation. Prior to joining BeiGene, Sean was Senior Director of Corporate Strategy at Takeda Pharmaceuticals. He previously held various roles at Shire plc, Baxalta, and Baxter in corporate development and commercial strategy functions. Prior to entering the biopharma industry, Sean worked at EY’s Transaction Advisory Services focusing on M&A-related financial consulting services. Sean received his bachelor’s degree from Peking University and his master’s degrees from the University of Illinois at Urbana-Champaign. He is a Chartered Financial Analyst (CFA).

Min Wei, Ph.D. is a senior advisor to Chief Business Executive and is a 20-year veteran of the drug discovery industry. Dr. Wei joined BeiGene at the start of the company as one of the key scientists and served as Head of Molecular Sciences prior to her current role. Dr. Wei was instrumental in the development of BeiGene’s early pipelines. Before joining BeiGene, Dr. Wei established and led the lab of Biochemistry and high throughput screening at BioDuro. In her prior positions, Dr. Wei was a research investigator and team leader at Incyte and GSK and contributed to numerous discovery programs in cancer, inflammation, cardiovascular diseases. She received her BS in chemistry from Tsinghua University, her PhD in Biochemistry from University of New Mexico and her post-doctoral training at MIT.

Dewan Zeng Ph.D., MBA, joined BeiGene in 2017 as Senior Director, Clinical Sciences, and transitioned to Business Development in January 2019. In her current role as Head of Search and Evaluation, she leads a team of professionals who identify and evaluate innovative products and technologies to complement BeiGene’s portfolio. Her team is also responsible for due diligence for in-licensing, out-licensing and clinical collaboration deals globally. Prior to joining BeiGene, Dewan worked at Pfizer, Gilead and CV Therapeutics, and held various leadership roles in clinical development and translational research. In her 23-year career in the pharmaceutical industry, she led multiple global development programs, from investigational new drug application to completion of Phase 1/Phase 2/Phase 3 clinical studies, and supported new drug application submissions and approvals of three pharmaceutical products in the U.S., Europe and China. Dewan received her B.S. in biochemistry from Peking University, her Ph.D. in biochemistry from the University of Virginia, and an MBA in global business strategy from Cal State University East Bay. She completed her postdoctoral training at the University of California San Francisco.